http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness
-
Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness
-
Pluri (PLUR) Secures Additional $3.5M Investment from Major Shareholder
-
Pluri Secures Additional $3.5 Million Investment from Major Shareholder at Premium to Market, Bringing Total Recent Financings to $10 Million
-
Pluri (PLUR) Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition
-
Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition
-
Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease
-
Pluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025
-
Pluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025
-
Pluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat Concerns
-
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing
-
Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority
-
Pluri's (PLUR) CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates
-
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates
-
Pluri (PLUR) Announces EUR 1M Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply
-
Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply
-
Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply
-
Pluri's (PLUR) Ever After Foods Secured $10M Strategic Investment
-
Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges
-
Pluri (PLUR) Reports US NIH Exercised Option to Fund $1.4M 2nd Year Budget for PLX-R18
-
U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract
-
Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale
-
Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale
-
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment
-
Pluri (PLUR) Granted U.S Patent for New Method
-
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method
-
Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences
-
Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report
-
Pluri (PLUR) Appoints Jim Roosevelt, Jr to its Board
-
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
-
Pluri (PLUR) CEO Issues Update
-
Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals
-
Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals
-
Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis
-
Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization
-
Pluri (PLUR) and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction
-
Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction
-
Pluri (PLUR) Reports Publication Showing PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study
-
Pluri’s PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation
-
Pluri (PLUR) Appoints Lorne Abony to its Board
-
Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors
-
U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri’s PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation
-
Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products
-
Israel’s Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity
-
Pluri (PLUR) CEO Issues Letter to Shareholders
-
Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept
-
Pluri (PLUR) Prices 7.89M Share Private Placement at $1.03/sh
-
Pluri Prices $8.2 million Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
-
Pluri wins BioTech Breakthrough Cell Innovation of the Year Award
-
Pluri to Present and Participate in Upcoming Conferences
